Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer - Cancer Therapy Advisor

Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.

Adding oleclumab or monalizumab to consolidation with durvalumab can improve clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC), a phase 2 trial suggests. C… [+3063 chars]

full article...